{Reference Type}: Journal Article
{Title}: miR-223-5p serves as a diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after PCI.
{Author}: Zhang S;Yang G;Chen Y;Liu W;
{Journal}: BMC Cardiovasc Disord
{Volume}: 24
{Issue}: 1
{Year}: 2024 Aug 13
{Factor}: 2.174
{DOI}: 10.1186/s12872-024-04088-3
{Abstract}: <B>BACKGROUND: </B>Acute coronary syndrome (ACS) is a serious cardiovascular disease that severely affects the quality of life and longevity of patients. MicroRNAs (miRNAs) play a key role in the progression of ACS with significant clinical value. The aim of this study was to examine the clinical value of miR-223-5p in ACS and on the occurrence of major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI).<BR><B>METHODS: </B>The plasma expression of miR-223-5p was detected by RT-qPCR. The correlation of miR-223-5p and cTnI or Gensini score was shown by the Pearson method. Risk factors for the development of ACS were analyzed by multivariate logistic regression. The efficacy of miR-223-5p in identifying patients with ACS was shown by ROC curve. The predictive value of miR-223-5p for MACE development in ACS patients within 6 months after PCI was assessed by Kaplan-Meier curve and multivariate Cox regression.<BR><B>RESULTS: </B>miR-223-5p levels were markedly elevated in ACS patients. miR-223-5p was found to be positively related to cTnI or Gensini score. miR-223-5p was a risk factor for ACS and significantly identified patients with ACS. MACE was more likely to occur after PCI in patients with high miR-223-5p levels, and miR-223-5p was an independent prognostic indicator of MACE.<BR><B>CONCLUSIONS: </B>miR-223-5p had diagnostic value for ACS and predicted MACE after PCI.